Table 25 Comorbidities of patients with atrial fibrillation using VKAs or OAC. (Continuation of Table 24)
| Â | Â | VKA | Dabigatran | Rivaroxaban | Apixaban |
|---|---|---|---|---|---|
Stroke | Paper | 15% | 15% | 18% | 21% |
| Â | UKW_11 | 2% | 13% | 5% | 13% |
| Â | UKW_16 | 3% | 26% | 3% | 2% |
Myocardial infarction | Paper | 11% | 7% | 6% | 7% |
| Â | UKW_11 | 3% | 1% | 2% | 1% |
| Â | UKW_16 | 2% | 2% | 4% | 1% |
Ischemic heart disease | Paper | 26% | 20% | 20% | 21% |
| Â | UKW_11 | 32% | 26% | 23% | 31% |
| Â | UKW_16 | 29% | 29% | 31% | 30% |
Heart failure | Paper | 19% | 14% | 15% | 16% |
| Â | UKW_11 | 31% | 25% | 26% | 34% |
| Â | UKW_16 | 35% | 26% | 31% | 38% |
Diabetes mellitus | Paper | 14% | 11% | 12% | 13% |
| Â | UKW_11 | 32% | 22% | 22% | 28% |
| Â | UKW_16 | 32% | 24% | 23% | 29% |
Hypertension | Paper | 47% | 44% | 44% | 43% |
| Â | UKW_11 | 69% | 68% | 63% | 67% |
| Â | UKW_16 | 67% | 71% | 61% | 64% |
Chronic kidney disease | Paper | 8% | 2% | 4% | 5% |
| Â | UKW_11 | 58% | 54% | 49% | 51% |
| Â | UKW_16 | 49% | 43% | 46% | 49% |